Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...
Business Intelligence | From W.D. Strategies on MSN
Dark truth about the Medicare Part B penalty: A one-day mistake that lasts a lifetime
You think you have everything figured out when you turn sixty-five. Social Security is on track, retirement savings look decent, and the future seems manageable. Then Medicare enrollment appears on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback